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ABSTRACT
Motivation: Alternative splicing allows a single gene
to generate multiple mRNAs, which can be translated
into functionally and structurally diverse proteins. One
gene can have multiple variants coexisting at different
concentrations. Estimating the relative abundance of each
variant is important for the study of underlying biological
function. Microarrays are standard tools that measure
gene expression. But most design and analysis has not
accounted for splice variants. Thus splice variant-speciﬁc
chip designs and analysis algorithms are needed for
accurate gene expression proﬁling.
Results: Inspired by Li and Wong (2001), we developed a
gene structure-based algorithm to determine the relative
abundance of known splice variants. Probe intensities
are modeled across multiple experiments using gene
structures as constraints. Model parameters are ob-
tained through a maximum likelihood estimation (MLE)
process/framework. The algorithm produces the relative
concentration of each variant, as well as an afﬁnity term
associated with each probe. Validation of the algorithm
is performed by a set of controlled spike experiments as
well as endogenous tissue samples using a human splice
variant array.
Contact: hui wang@affymetrix.com
INTRODUCTION
Alternative splicing is an important regulatory mecha-
nism, often controlled by developmental or tissue-speciﬁc
factors. (Smith et al., 1989; Hodges and Bernstein, 1994).
Many alternatively spliced mRNAs may be expressed
simultaneously in the same tissue, yielding an extensive
set of proteins with distinct functions (Smith et al.,
1989; Kochiwa et al., 2002). In human, approximately
30–60% of genes undergo alternative splicing (Sutcliffe
∗To whom correspondence should be addressed.
and Milner, 1988; Croft et al., 2000; Lander et al., 2001;
Venter et al., 2001; Kochiwa et al., 2002). In some
cases, splice variants are associated with human diseases
(Stallings-Mann et al., 1996; Liu et al., 1997; Siffert et
al., 1998).
Microarray technology has become a standard method
for gene expression proﬁling. However, most microarray
design and analysis is limited to detecting and measur-
ing changes of expression for each gene. The current
methods ignore, implicitly or explicitly, the presence of
multiple splice variants in the same target mRNA pool.
The reasons are many, but include the complexity of
microarray designs to measure the multitude of splicing
products and limitations of target labeling techniques.
Being able to measure variant-level concentrations is
important for accurate expression proﬁling, and con-
sequently for obtaining a better understanding of the
biological processes. Recently, several studies have
applied microarray technology to this issue (Hu et al.,
2001; Miki et al., 2001; Shoemaker et al., 2001; Clark et
al., 2002; Kapranov et al., 2002; Yeakley et al., 2002).
Genomic tiling arrays and exon arrays can be used to
identify co-regulated exons, which allows the inference of
variant mixtures (Shoemaker et al., 2001; Kapranov et al.,
2002). Expression arrays with multiple probes have been
retrospectively analyzed to identify exons that are differ-
entially included or skipped in a tissue-speciﬁc manner
(Hu et al., 2001). RNA-mediated ligation combined with
arrays presents a novel method for detecting exon-exon
junction information of known splice variants (Yeakley
et al., 2002). Most recently splice junction spanning
oligonucleotides representing nearly all yeast splicing
events have been used to monitor the genome-wide effects
of splicing factor mutations in yeast (Clark et al., 2002),
suggesting exon joining information can be accessed
using oligonucleotide arrays. To date, there is no analysis
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that provides quantitative measure of different variants’
expression levels.
Li and Wong adopted a model-based approach to
estimate gene expression by ﬁtting expression data at the
probe level across multiple experiments (Li and Wong,
2001). Their model applies a simple formula linking
intensity to concentration using the fact that all probes
from the same probe set hybridize to the same target. This
approach can reasonably address probe speciﬁc behavior
and detect and eliminate outlier probes to give better
expression estimates.
Inspired by their method, we developed an algorithm to
estimate splice variant expression level by incorporating
gene structure information. The gene structure speciﬁes
the features of each variant, where features can be both ex-
ons and exon-exon junctions. Probes are tiled selectively
along certain features. Thus the probe intensity reﬂects
the total concentration of the feature to which the probe
belongs. Since a combination of features deﬁnes a variant,
probe intensity then reﬂects the total concentration of
one or more transcripts. By capturing these relationships,
we are able to deconvolute the relative abundance of
each variant in a set of samples. Data from these probes
is ﬁt across multiple experiments with a squared error
loss function used to minimize the differences between
predicted and observed values. Parameters are estimated
iteratively using a maximum likelihood estimation (MLE)
framework. The algorithm outputs the relative concentra-
tion of each variant, as well as an afﬁnity term associated
with each probe. Its efﬁciency is demonstrated through
experiments on spiked clones and endogenous tissue
samples.
METHODS AND MATERIALS
A special splice variant chip was designed using 21 well-
characterized genes. The chip design process includes
sequence selection, gene selection and probe selection.
Sequence selection
All mRNA and cDNA sequences were mapped to the
Golden Path Genomic sequences (April 2001 release)
using psLayout (Kent and Haussler, 2001). Based on
the alignments, we characterized genes and generated
unique splice variants. Then gene features including
exons, introns and junctions were extracted and loaded
into a relational database.
Gene selection
21 genes were selected from the literature (including
ACHE, APAF1, BCL2L1, BCLG, BRCA1, CALCA,
CALCR, CASP2, CD44, DNMT3B, FGF1, IL15, ITGA3,
ITGA6, MAPT, MYLK, PSEN1, THRA, TNNT2, TPM2
and WNT2B). These genes were selected because their
alternative splicing has been well studied using standard
Fig. 1. Probe tiling.
techniques of RNA analysis. The regulation of these genes
at the level of splicing plays an important role in biolog-
ical processes such as cancer and muscle development.
Sequence information of each gene is extracted from the
sequence selection database described above. A splice
variant chip is then designed based on the information of
these 21 genes.
Probe selection
There are two main types of probes: exon probes
and junction probes. Exon probes are selected using
Affymetrix’s expression probe selection software (Mei
et al., 2003). If two exons overlap, probes are selected
from the overlapping regions and the unique regions.
Junction probe tiling is position-constrained. We choose
eight symmetrically positioned probes across junctions.
The center position of these probes relative to the junction
are −5,−3,−2,−1,+1,+2,+3,+5. Figure 1 summarizes
the probe tiling strategy.
Clones
Three CD44 splice variants represented by IMAGE
clone ID: 588908 (clone 1), 118372 (clone 2) and
3638681 (clone 3) were purchased from Invitrogen Inc.
The simpliﬁed structures of these clones are shown in
Figure 5B.
ALGORITHM
Probe models
Based on the Li and Wong reduced model (Li and Wong,
2001), the relationship between probe intensity and target
transcript concentration measured by probes and probe
afﬁnities can be expressed by the following formula:
y = PM− MM = αx + ε (1)
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Fig. 2. Example of matrix representation. The example gene has
two variants with 3 features and each feature contains 2 probes.
Variant 1 has feature 1 and 3, while variant 2 has feature 2 and 3.
Two experiments are performed.
Here, PM and MM are probe intensities for perfect
match and mismatch respectively, the target transcript
concentration measured by a probe is denoted by x, α
denotes the probe afﬁnity term and we use ε to denote the
error term where ε ∼ N(0,σ2).
Since a transcript is usually represented by multiple
probes and has different concentrations in different
experiments, the above formula is generalized to:
yij = aix j + εij (2)
where i is the index for probes and j is the index for
experiments. We extend Equation (2) to the problem of
measuring the concentrations of several splice variants.
Models in the context of gene structure and
application to alternative splicing
A transcript may be uniquely identiﬁed by a set of
features, each of which may be represented by a series
of probe sequences. A gene feature can be either an
exon, intron, partial exon, intron, or a junction (exon-
exonjunction,exon-intronjunction,intron-exonjunction).
Exon features can be partitioned further depending on
whether the exon is a cassette exon or an exon overlapping
with others. Intron features may be treated the same way.
Probes can be mapped to the features that contain them,
and in turn, the features can be mapped to the transcripts
that contain them. We represent these relationships via
matrices.
Typically,agenestructurecontainsallknowntranscripts
of each gene and the feature composition for each
transcript, but it also can contain only a subset of
features of interest. The relationship between features
and transcripts can be represented by a q-by-t matrix
G = (glk) containing binary values of 1 or 0, where
glk = 1 means feature l is present in transcript k, while
glk = 0 means this feature is absent. The total number of
transcripts is t and q is the total number of features. The
transcriptconcentrationsofagivengeneinallexperiments
are represented by a t-by-x matrix T = (tkj), where tkj
represents the concentration of transcript k in experiment
j.Here x isthetotalnumberofexperiments.LetC = (clj)
be the q-by-x matrix deﬁned by C = GT. It is easily seen
that clj is the concentration of feature l in experiment j.
The mapping of probes to features is represented in a
similar way by a matrix F. Multiple probes can be chosen
to represent each gene feature and some probes can be
in more than one feature. Matrix F = ( fil) is a p-by-q
matrix with values 0 or 1, where p is the total number of
probes, q is the total number of features, fil equals 1 if
probe i belongs to feature l, and filequals 0 otherwise.
Let X = FC. Thus X = (xij) is a p-by-x matrix and
xij is the sum of the concentrations in experiment j of all
the features to which probe i belongs. By the deﬁnition of
C and F, xij is the actual concentration of all the target
transcripts in experiment j interrogated by probe i.
We develop an equation analogous to (1) that relates
the matrix X of actual concentrations to the matrix Y
of observed probe intensities. Let A = (aii) be a
p-by-p diagonal matrix where aii represents the probe
afﬁnity term. The predicted probe intensities can then
be expressed as AX = AFGT. The observed probe
intensities are given by a p-by-x matrix Y = (yij), where
yij is the intensity of probe i for experiment j. The
observed probe intensities will equal the predicted probe
intensities plus experimental error denoted by E = (εij)
as shown in Equation (2). Thus the matrix version of
Equation (2) is Y = AX+ E = AFGT + E. To illustrate
this formulation, Figure 2 shows all matrices of a simple
genewith2transcripts,3featuresand2probesperfeature.
Model ﬁtting and minimization
We want to minimize the differences between the pre-
dicted and observed intensities for all probes using a
maximum likelihood framework. Since we are assum-
ing Gaussian noise, this leads to a standard regression
framework, so we use the squared error loss function.
The squared difference between predicted and observed
intensity values for all probes of each gene can be written
as function f (A,T) = (||Y − AFGT||2)2. We want to
minimize f over the unknowns A and T.
Some constraints or penalty terms are needed in order
to solve this minimization problem because it is under-
constrained as stated. Thus the following constraints are
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added:
z  
i=1
a2
ii = constant (3)
aii  0 (4)
tmj  0 (5)
Where z in equation (3) is the total number of probes
used in the constraint. Equations (4) and (5) reﬂect the fact
thatconcentrationandafﬁnitytermsmustbenon-negative.
Alternatively to (3), we can add γ(||A||2)2 to f , where
γ is a small positive constant.
Solving the minimization problem with constraints
(3)–(5) corresponds to maximum likelihood estimation
(MLE). This can be approached by alternately ﬁxing A
and solving for T, then ﬁxing T and solving for A until
convergence. Each step in this procedure is a linear least
squares minimization with linear constraints. The ﬁnal
values of T and A yield the relative concentration of each
transcript variant and the relative afﬁnity term of each
probe.
RESULTS
We validated our model using two approaches. First, we
applied the model to a set of controlled experiments with
spiked clones, and compared predicted concentrations to
actualconcentrations.Second,weappliedittotheanalysis
of endogenous tissue samples, conﬁrming the results with
the TaqMan PCR assay. All experiments used a custom-
designed Affymetrix microarray for detecting the 21 well-
documented human genes that exhibit splice variation.
Two-variant spike experiments
We tested the accuracy and sensitivity of the algorithm
with dilution experiments (using yeast complex back-
ground) using target preparations derived from pairs of
cDNA clones representing two splice variants from the
same gene. In one set, we mixed target derived from
two CD44 variants (clone 1 and clone 2) with differing
concentrations: the ﬁrst variant ranged from 0 to 64 pM
and the second variant ranged from 64 pM to 0 pM with
the total concentration held constant at 64 pM. By diluting
the whole set 4 and 16 times, we obtained further results
for titration experiments with total concentrations of
16 pM and 4 pM respectively. The variant concentrations
as well as the results from the algorithm are detailed in
Figure 3.
In all three sets of experiments, the predicted concentra-
tion of each variant (indicated by bars in Fig. 3) is similar
to the actual concentration (indicated by lines in Fig. 3).
Furthermore, the individual concentrations are consistent
between different experiments. For instance, the 8 pM
concentration of variant 2 in the 64 pM set of experiments
is comparable to the 8 pM sample in the 16 pM set, and
the predictions for 4 pM concentration are similar in all
three sets of experiments. Each ratio of the two variants
was tested three times: at the 64 pM, 16 pM, and 4 pM
total concentration levels. In each case, the predicted
concentration mirrored the actual concentrations. Thus,
we are able to compare the relative abundance of the
targets in different samples. The results indicate that the
algorithm is very sensitive, as it can detect concentrations
as low as 0.5 pM.
This two-variant spike experiment was also done with
different sets of genes, including ACHE, TPM2, MYLK
and MAPT. Similar results were obtained for each of the
differentvariantpairs(datanotshown).Figure4showsthe
correlation of the predicted concentration with the actual
concentrations of the two variants of CD44 and TPM2.
The R2 scores between the predicted concentrations and
the actual concentrations for these tested pairs are greater
than 0.94.
Three-variant spike experiments
In order to test a more general case, a third CD44
variant (clone 3) was added. The experiment was designed
to test all possible combinations of clones at 0 and
4 pM under simple background. In general, the predicted
concentrations are consistent with the actual concentration
of each variant as shown in Figure 5A.
TPM2 tissue experiments
Further validation was performed on tissue samples,
studying the gene TPM2. Beta-tropomyosin gene contains
in its central portion two mutually exclusive exons (A
and B). Variants containing exon A (TPM2-A) are mainly
present in skeletal muscle, while variants containing exon
B (TPM2-B) are present in non-muscle and smooth
muscle tissues (MacLeod et al., 1985; Helfman et al.,
1986; Widada et al., 1988; Clouet d’Orval et al., 1991;
Lees-Miller and Helfman, 1991; Novy et al., 1993;
Beisel and Kennedy, 1994; Pittenger et al., 1995; Gallego
et al., 1996). Figure 6A shows the predicted relative
concentrations of TPM2-A and TPM2-B of 7 human
tissues. Based on the prediction, TPM2-A is observed in
adult and fetal skeletal muscle, as well as esophagus and
fetal heart. TPM2-B is not observed in skeletal muscle, as
expected, but is observed in esophagus, stomach, uterus,
and fetal umbilical cord (Helfman et al., 1986). The result
is consistent with Taqman quantitative PCR validation for
selected tissues (Fig. 6B).
DISCUSSION
This work demonstrates that our gene structure-based ap-
proach can be used to estimate the relative abundance of
splice variants. The algorithm generates the relative con-
centration of each variant and an afﬁnity term associated
i318Gene structure-based splice variant deconvolution using a microarry platform
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Fig. 3. Predicted relative concentration in two-variant titration experiments. Two CD44 variants were mixed at 30 different known
concentrations. The experiments as well as the actual concentrations of each variant pair are indicated by X-axis. There are three sets of
experiments. In each set, we vary the concentration of each variant while keeping the total concentration ﬁxed. The total concentration of
each set is 64 pM (samples 1–11), 16 pM (samples 13–23) and 4 pM (samples 24–30) respectively. Sample 12 is a control experiment.
The Y-axis indicates the scaled predicted concentration of each variant as well as the total concentrations. For easy comparison, the actual
concentrations are also plotted in the same chart.
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Fig. 4. Correlations between predicted concentrations and actual concentrations. X-axis is the actual concentrations of each of the
two variants (indicated by bullets and triangles) in 30 experiments. Y-axis is the predicted relative concentration of each variant in these
experiments.
with each probe. The predicted concentrations can be used
to compare the expression level of multiple variants of the
same gene in a sample as well as expression changes of
the same variant across multiple samples.
Generic model
As described above, the reduced probe model assumes
that mismatch probes account for all non-speciﬁch y -
bridizations. However this is often not true. A more
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generic model includes a background term for each probe.
The probe model in formula (1) is then expressed as:
y = ax + b + ε. (6)
If we let the column vector   b = (bi) represent probe-
speciﬁc background terms,   1 = (1j) be the row vector
of 1s, and B =   b  1 be the outer product of these, then as
above we can generalize (6) to
Y = AD+ B + ε = AFGT + B + ε (7)
Since B is treated as a property of probe, in the
minimization process we solve for B at the same time we
solve for the afﬁnity term A.
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Limitations of the algorithm
Degeneracy occurs when there is no unique solution
for each of the variants. As mentioned above, the G
matrix represents the relationship between transcripts and
features of interest. It is obvious, for example, if the
number of features is less than the number of transcripts,
there is no unique solution. A simple alternative is
to combine and solve for the concentration of several
transcripts altogether. Other complications such as the
‘ill-conditioned’ situation, a classical matrix computation
problem, can make computation quite difﬁcult. Many
techniques such as orthogonal transformation can be
applied to help solve the problem.
This algorithm is intended for splice variant typing,
not discovery. A limitation exists when the input gene
structure is incorrect, which can happen when there are
unknown transcripts present in the test samples. The
robustness of the method is a topic of ongoing research.
Three-variant spike experiments
Even though the predicted concentrations are consistent
with the variants’ actual concentrations, some inconsisten-
cies are evident (Fig. 5A). First, the concentration of vari-
ant 1 appears to be lower than that of variant 2 and 3 (ex-
periments 2, 3 and 5). Given careful examination and gel
analysis, it appears that the actual spiked concentrations
of variants 2 and 3 are higher than 4 pM due to a con-
sistent error in estimation of the molar amount of spiked
transcripts. This error is probably caused by the greater
efﬁciency of full length transcript synthesis for the shorter
variant transcripts in our in vitro transcription reactions.
Second, both experiment 5 (0,4,0) and 6 (0,4,4) show
non-zero concentrations of variant 1. We hypothesize that
itisrelatedtoasplicevariantspeciﬁcjunctioneffect:cross
hybridization from partially-overlapping junctions, specif-
ically those beginning or ending at the same exon. In this
example, the junction probes of variant 1 partially over-
lap with those of variant 2 and 3 (Fig. 5B). We call these
partially-overlapping junctions competitive junctions. Fu-
ture work will include development of a model for this
junction-speciﬁc effect.
In conclusion, we have developed an efﬁcient algorithm
for estimating the relative concentrations of splice vari-
ants. This algorithm can potentially help in obtaining a
more accurate interpretation of microarray data and thus
a better understanding of biological functions.
ACKNOWLEGEMENTS
The authors would like to thank Tom Ryder for scientiﬁc
discussions of the project. We are also grateful to Keith
Jones for careful reading and critical comments on the
manuscript.
REFERENCES
Beisel,K.andKennedy,J.(1994)Identiﬁcationofnovelalternatively
spliced isoforms of the tropomyosin-encoding gene, TMnm, in
the rat cochlea. Gene, 143, 251–256.
Clark,T.A., Sugnet,C.W. et al. (2002) Genomewide analysis of
mRNA processing in yeast using splicing-speciﬁc microarrays.
Science, 296, 907–910.
Clouet d’Orval,B., d’Aubenton Carafa,Y. et al. (1991) RNA sec-
ondary structure repression of a muscle-speciﬁc exon in HeLa
cell nuclear extracts. Science, 252, 1823–1828.
Croft,L., Schandorff,S. et al. (2000) ISIS, the Intron Information
System, reveals the high frequency of alternative splicing in
human genome. Nature Genet., 24, 340–341.
Gallego,M., Sirand-Pugnet,P. et al. (1996) Tissue-speciﬁc splic-
ing of two mutually exclusive exons of the chicken beta-
tropomyosin pre-mRNA: positive and negative regulations.
Biochimie, 78, 457–465.
Helfman,D., Cheley,S. et al. (1986) Nonmuscle and muscle
tropomyosin isoforms are expressed from a single gene by al-
ternative RNA splicing and polyadenylation. Mol. Cell Biol., 6,
3582–3595.
Hodges,D. and Bernstein,S. (1994) Genetic and biochemical analy-
sis of alternative RNA splicing. Adv. Genet., 31, 207–281.
Hu,G.K., Madore,S.J. et al. (2001) Predicting splice variant from
DNA chip expression data. Genome Res., 11, 1237–1245.
Kapranov,P., Cawley,S.E. et al. (2002) Large-scale transcriptional
activity in chromosomes 21 and 22. Science, 296, 916–919.
Kent,W.J. and Haussler,D. (2001) Assembly of the working draft of
the human genome with GigAssembler. Genome Res., 11, 1541–
1548.
Kochiwa,H., Suzuki,R. et al. (2002) Inferring alternative splicing
patterns in mouse from a full-length cDNA library and microar-
ray data. Genome Res., 12, 1286–1293.
Lander,E.S., Linton,L.M. et al. (2001) Initial sequencing and
analysis of the human genome. Nature, 409, 860–921.
Lees-Miller,J. and Helfman,D. (1991) The molecular basis for
tropomyosin isoform diversity. Bioessays, 13, 429–437.
Li,C. and Wong,W.H. (2001) Model-based analysis of oligonu-
cleotide arrays: expression index computation and outlier detec-
tion. Proc. Natl Acad. Sci. USA, 98,3 1 –36.
Liu,W., Qian,C. et al. (1997) Silent mutation induces exon skip-
ping of ﬁbrillin-1 gene in Marfan syndrome. Nature Genet., 16,
328–329.
MacLeod,A., Houlker,C. et al. (1985) A muscle-type tropomyosin
in human ﬁbroblasts: evidence for expression by an alternative
RNA splicing mechanism. Proc. Natl Acad. Sci. USA, 82, 7835–
7839.
Mei,R., Hubbell,E. et al. (2003) Probe selection for high-density
oligonucleotide arrays. Submitted.
Miki,R., Kadota,K. et al. (2001) Delineating developmental and
metabolic pathways in vivo by expression proﬁling using the
RIKEN set of 18816 full-length enriched mouse cDNA arrays.
Proc. Natl Acad. Sci. USA, 98, 2199–2204.
Novy,R., Lin,J. et al. (1993) Human ﬁbroblast tropomyosin
isoforms: characterization of cDNA clones and analysis of
tropomyosin isoform expression in human tissues and in normal
and transformed cells. Cell Motil Cytoskeleton, 25, 267–281.
Pittenger,M., Kistler,A. et al. (1995) Alternatively spliced exons of
the beta tropomyosin gene exhibit different afﬁnities for F-actin
i321H.Wang et al.
and effects with nonmuscle caldesmon. J. Cell Sci., 108, 3253–
3265.
Shoemaker,D.D., Schadt,E.E. et al. (2001) Experimental annotation
of the human genome using microarray technology. Nature, 409,
922–927.
Siffert,W., Rosskopf,D. et al. (1998) Association of a human G-
protein beta 3 subunit variant with hypertension. Nature Genet.,
18,4 5 –48.
Smith,C., Patton,J. et al. (1989) Alternative splicing in the con-
trol gene expression. Annu. Rev. Genet., 23, 527–577.
Stallings-Mann,M., Ludwiczak,R. et al. (1996) Alternative splicing
of exon 3 of the human growth hormone receptor is the result
of an unusual genetic polymorphism. Proc. Natl Acad. Sci. USA,
93, 12394–12399.
Sutcliffe,J.G. and Milner,R.J. (1988) Alternative mRNA splicing:
the shaker gene. Trends Genet., 4, 297–299.
Venter,J.C., Adams,M.D. et al. (2001) The sequence of the human
genome. Science, 291, 1304–1351.
Widada,J., Ferraz,C. et al. (1988) Complete nucleotide sequence
of the adult skeletal isoform of human skeletal muscle beta-
tropomyosin. Nucleic Acids Res., 16, 3109.
Yeakley,J.M., Fan,J.B. et al. (2002) Proﬁling alternative splicing
on ﬁber-optic arrays. Nat. Biotechnol., 20, 353–358.
i322